reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Structure Therapeutics Inc.

GPCR · Nasdaq

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$835Mpublic float
2023-11-14most recent failure

Score over time

01220232024202520262023-07-01 · score 12023-06-05 auditor change2023-10-01 · score 12023-06-05 auditor change2024-01-01 · score 22023-11-14 filed late (10-Q) · auditor2023-06-05 auditor change2024-04-01 · score 22023-11-14 filed late (10-Q) · auditor2023-06-05 auditor change2024-07-01 · score 12023-11-14 filed late (10-Q) · auditor2024-10-01 · score 12023-11-14 filed late (10-Q) · auditor

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Structure Therapeutics Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Third Quarter 10-Q”) on or prior to its prescribed due date without unreasonable effort or expense due to a delay in obtaining and compiling financial information required to be included in the Third Quarter 10-Q. Specifically, the Company’s interim unaudited condensed consolidated financial statements for the three months ended September 30, 2022 (the “2022 Interim Financial Statements”) were not previously reviewed in accordance with Public Company Accounting Oversight Board Auditing Standard 4105, Reviews of Interim Financial Information (“PCAOB AS 4105”). The Company has concluded it is appropriate to delay the filing of the Third Quarter 10-Q while an independent registered public accounting firm completes the review of the 2022 Interim Financial Statements in accordance with PCAOB AS 4105. The Company plans to file the Third Quarter 10-Q no later than the fifth calendar day following the prescribed due date. In addition, the interim unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2022 included in the Company’s Form 10-Q for the quarter ended June 30, 2023 (the “Second Quarter 10-Q”) were not previously reviewed by an independent registered public accounting firm in accordance with PCAOB AS 4105. As a result, the Second Quarter 10-Q is deemed substantially deficient until the reviews of such financial statements are completed by an independent registered public accounting firm and the Second Quarter 10-Q is not considered timely filed or current

NT 10-Q, filed 2023-11-14 · auditor

What it filed

2023-11-14filed late (10-Q)auditor SEC →

Structure Therapeutics Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2023 (the “Third Quarter 10-Q”) on or prior to its prescribed due date without unreasonable effort or expense due to a delay in obtaining and compiling financial information required to be included in the Third Quarter 10-Q. Specifically, the Company’s interim unaudited condensed consolidated financial statements for the three months ended September 30, 2022 (the “2022 Interim Financial Statements”) were not previously reviewed in accordance with Public Company Accounting Oversight Board Auditing Standard 4105, Reviews of Interim Financial Information (“PCAOB AS 4105”). The Company has concluded it is appropriate to delay the filing of the Third Quarter 10-Q while an independent registered public accounting firm completes the review of the 2022 Interim Financial Statements in accordance with PCAOB AS 4105. The Company plans to file the Third Quarter 10-Q no later than the fifth calendar day following the prescribed due date. In addition, the interim unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2022 included in the Company’s Form 10-Q for the quarter ended June 30, 2023 (the “Second Quarter 10-Q”) were not previously reviewed by an independent registered public accounting firm in accordance with PCAOB AS 4105. As a result, the Second Quarter 10-Q is deemed substantially deficient until the reviews of such financial statements are completed by an independent registered public accounting firm and the Second Quarter 10-Q is not considered timely filed or current

2023-06-05auditor changed or resigned SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com